MapLight Therapeutics, Inc. (MPLT)
NASDAQ:MPLT
Want to see MPLT full AI Analyst Report?
MPLT Stock Chart & Stats
$17.49
--
Market closed
$17.49
--
Day’s Range― - ―
52-Week Range$12.24 - $33.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.63K
Market Cap
$1.29B
Enterprise Value-$26.98M
Total Cash (Recent Filing)$310.11M
Total Debt (Recent Filing)$5.59M
Price to Earnings (P/E)―
Beta1.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,618,164
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit47.00
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$40.38Price Target Upside130.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and sizable equity provide durable financial flexibility for a clinical-stage biotech. This capital structure reduces near-term refinancing risk, supports continued R&D spending through multiple trial readouts, and gives management room to pursue strategic options without immediate distress.
Multi-year Cash RunwayA multi-year cash balance sized to fund operations into 2027 is a meaningful structural buffer for completing Phase 2 programs and preparing pivotal plans. This runway lowers immediate financing pressure and allows execution of clinical plans over 12–24 months absent material trial setbacks.
Diversified Phase 2 CNS PipelineMultiple Phase 2 programs across schizophrenia, autism and Alzheimer’s psychosis with an FDA Fast Track designation create structural upside beyond any single study. A diversified CNS portfolio and regulatory recognition increase the probability of at least one de‑risking catalyst and potential partnership or licensing opportunities.
Bears Say
Accelerating Cash BurnMaterial year-over-year increases in losses and operating cash outflows indicate a rising expense base tied to intensified clinical activity. Persistently accelerating cash burn will consume the balance sheet faster, increasing dilution and funding risk if clinical timelines slip or additional capital markets access tightens.
Pre-revenue OperationsThe company remains pre-revenue with no product sales, meaning long-term value depends entirely on clinical and regulatory success. Without commercialization, there is no operating leverage to absorb R&D spend, making profitability and sustainable margins contingent on future, uncertain approvals and market adoption.
Funding And Execution RiskNegative and volatile free cash flow raises structural funding risk: ongoing operations will likely require external capital absent successful monetization. Dependence on upcoming trial readouts as de‑risking events makes the company vulnerable to binary clinical outcomes that could materially affect future financing terms and strategic options.
MapLight Therapeutics, Inc. News
MPLT FAQ
What was MapLight Therapeutics, Inc.’s price range in the past 12 months?
MapLight Therapeutics, Inc. lowest stock price was $12.24 and its highest was $33.28 in the past 12 months.
What is MapLight Therapeutics, Inc.’s market cap?
MapLight Therapeutics, Inc.’s market cap is $1.29B.
When is MapLight Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MapLight Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is MapLight Therapeutics, Inc. overvalued?
According to Wall Street analysts MapLight Therapeutics, Inc.’s price is currently Undervalued.
Does MapLight Therapeutics, Inc. pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
What is MapLight Therapeutics, Inc.’s EPS estimate?
MapLight Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. has 42,618,164 shares outstanding.
What happened to MapLight Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MapLight Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MPLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MapLight Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.38 (130.85% Upside)
$40.38 (130.85% Upside)
Hedge Fund Trend
Decreased
By 301.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $804.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-69.06%
Trailing 12-Months
Asset Growth
275.37%
Trailing 12-Months
Company Description
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
MPLT Stock 12 Month Forecast
Average Price Target
$40.38
▲(130.85% Upside)
Scinai Immunotherapeutics
―
Sensei Biotherapeutics
―
GRI Bio
―
Dermata Therapeutics
―
Azitra Inc
―
Ownership Overview
63.47% Insiders
6.26% Mutual Funds
10.50% Other Institutional Investors
15.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---